The Federal Food and Drug Administration, or FDA is generally considered a powerful gatekeeper, able to deliver or withhold life-saving cures and create or destroy economic windfalls. As the decades go by, and technologies, diseases, public health demands, and politics evolve, we can identify patterns of change, action and inter-action among some of these traditional stakeholders in the FDA's policy sphere. A careful examination of this agency's colorful history can shed light on central features of the agency's policy process, which has been quite receptive to its stakeholders and adaptive to change over the decades and, in turn, show the way for development in lanes which do not fit neatly into the current paradigms offered by the agency. This paper will explore the history of FDA policy process, through examination of seminal moments in FDA history, the prominent actors and focusing events within them, and the outcomes of those events, in an attempt to illuminate a pattern of behavior or processes by which a struggling field of pharmaceutical development such as interventions for hearing loss can advance.
Introduction
The Federal agency known as the Food and Drug Administration, or FDA, is many things to many people. To the American public, it has traditionally been revered as a protector of public health and noble opponent to potentially harmful quack medicine. To the pharmaceutical, medical device and biologics industries, it has generally been considered a powerful gatekeeper, able to create or destroy economic windfalls. To the higher echelons of American political actors, including Congress and the President, the FDA is often used as a political mechanism of action. As the decades go by, and technologies, diseases, public health demands, and politics evolve, we can identify patterns of change, action and inter-action among some of these traditional stakeholders in the FDA's policy sphere. A public which is increasingly skeptical of all government agencies begins to seriously entertain criticisms of the oncebeloved agency (Zelizer, 2012) ; an industry that is increasingly compartmentalized into niche areas of concern and lifecycles shows equivalently increasing frustration with the heavy burdens of FDA bureaucracy; Congress flips from criticisms of FDA granting approvals too quickly, to lashing criticisms of delays in approval rates; and policies created to protect and inspire innovation become a hotbed of criticism for stymying development of technologies intended to treat the poor and indigent. The constant in the turmoil is the web of complexity by which the FDA operates internally and in collaboration with related Federal agencies, including the National Institutes of Health (NIH), the Department of Defense (DOD), Ncational Trade Commission (NTC), the Department of Health and Human Services (DHHS), the Public Health Service (PHS) and its subsidiaries like the Center for Disease Control (CDC), among others. The entirety of the FDA universe in all its history, controversy and seemingly limitless power has created a shroud of mysticism and bafflement through which its primary customers e the patients, medical community, and technology sponsors e must learn to see through in order to successfully interact with the agency.
A careful examination of this agency's colorful history, however, can easily dissolve that shroud and shed light on central features of the agency's policy process, which has, in reality, been quite receptive to its stakeholders and adaptive to change over the decades. Such an understanding of the workings of the FDA can in turn show the way for development in lanes which do not fit neatly into the current paradigms offered by the agency. The purpose of this paper is to attempt just that: to explore the history of FDA policy process, through examination of seminal moments in FDA history, the prominent actors and focusing events within them, and the outcomes of those events, in an attempt to illuminate a pattern of behavior or processes by which a struggling field of pharmaceutical development can advance. In his article which attempts to "attempt to identify and analyze the major historical changes and influences that have shaped the regulation of biotechnology by FDA," David L. Stepp argues that one can predict the future of FDA policy changes if equipped with, "a knowledge of the standard ways in which FDA policy has evolved historically, the pressures and influences that prompted those historical changes, and an appreciation of the influences that exist currently and their likely effect" (Stepp, 1999) . In a similar fashion, this paper will use examples from past and present dealings with the FDA, in a novel attempt to show how a struggling field of FDA-regulated development can craft its own pathway through and with the seemingly "Wizard of Oz"-like agency. Specifically, this paper will attempt to demonstrate the actual flexibility of the FDA, and, firm in that perspective, to carve out a feasible pathway for developers and stakeholders in pharmaceutical interventions for hearing loss, in particular, to navigate toward an approved drug or set of drugs in a coordinated effort with the FDA and other invested Federal agencies.
FDA history: a review from a policy process perspective
Like most Federal agencies, the FDA is a heavily loaded bureaucracy which sits under the Department of Health and Human Services; but unlike most Federal agencies, the FDA is responsible for one of the most highly regulated industries in the United States, the pharmaceutical industry (Carpenter, 2004) . Additionally, it is responsible for the regulation of foods; medical devices; radiationemitting products; vaccines, blood and biologics; cosmetics; and tobacco products (FDA, 2015) . The standard product oversight categories for medical development encompass many subsets and, conversely, also manage to regulate supra-categories like biotechnologies which "do not comprise a distinct product group within FDA, but are instead categorized on a product-by-product basis as a "food", "drug", "device", or "biologic" (Stepp, 1999) . In order to properly frame the conversation at hand, and create a sense of understanding of this massive bureaucratic body, it is important to begin with a brief understanding of the timeline of development and evolution of the FDA. The FDA's timeline functionally begins with the Pure Food and Drugs Act of 1906. With that Act, Congress first granted FDA significant authority to regulate drugs with civil and criminal penalties, prohibiting "interstate commerce in "adulterated" or "misbranded" drugs" (Stepp, 1999) . Under the 1906 Act, a drug was recognized as such if it was "recognized by the United States Pharmacopoeia or National Formulary for internal or external uses … [or] intended to be used for the cure, mitigation, or prevention of disease in either man or other animals" (Stepp, 1999) . However, in 1911, the Supreme Court of the United States "substantially limited the scope of the 1906 act by interpreting the definition of "misbranded" to prohibit only claims that were false or misleading as they related to the identity or ingredients of the drug mixture, but not to prohibit false or misleading claims regarding the therapeutic effects of a drug" (Stepp, 1999 ). This distinction would drastically limit the authority and scope of the early FDA, as congressionally enacted into the Amendment of 1912, or the Sherley Amendment, for the next 25 years. Notably, it would also be the last major decision in the courts ruled that was not in favor of the FDA.
In 1937, the poisoning deaths of over 70 people caused by an elixir called Sulfanilamide proved the inability of the FDA to protect the public under the constrained authorities provided by the 1906 Act and Sherley Amendments (Stepp, 1999) . Basic scientific tests could have prevented the elixir from being released into the public, but the FDA's only authority was to restrict the branding as an "elixir", technically defined as an alcohol-based solvent, which Sulfanilamide was not (Stepp, 1999) . As a direct result of this focusing event, Congress enacting the Federal Food, Drug and Cosmetics (FDCA) Act of 1938, otherwise known as "the 1938 Act", which is still the foundation of FDA authority today.
The 1938 Act provided the FDA with "authority for premarketing review of drugs" which set up both new Investigational New Drug (IND) and New Drug Application (NDA) systems. Further, although the FDA had been petitioning Congress for the ability to expand its authority over advertising allowed by manufactures, Congress instead gave that authority to another Federal agency, the Federal Trade Commission (FTC). In response, the FDA greatly expanded its own definition of "mislabeled" to compensate for its lack of inherent authority on the branding and labeling of drug products (Coleman, 2014) . The FDA's new strict "definition of "mislabeled" reflected both changes in the state of medical evidence and in the views of courts [, who upheld the interpretation,] toward FDA's exercise of misbranding jurisdiction. This new definition also solved the problems created by the Sherley Amendment by no longer requiring FDA to present evidence concerning the intent or state of mind of the manufacturer; FDA needed only demonstrate that the product did not meet the claims of its labeling" (Stepp, 1999) . Further, the 1938 Act added FDA authority to inspect manufacturing facilities, [and] creat [ed] an easier pathway to criminal convictions of corporate officers (Stepp, 1999) . However, the FDA was still, by the authority vested in the 1938 Act, limited to concerns of safety, and only that of new drugs, and had no control over claims of actual efficacy. All a manufacturer had to do was claim their products were "generally recognized as safe" to keep the FDA off their back, as the FDA held the burden of proving otherwise. Many generic drugs were able to hit the market, claiming other previous NDAs of the "pioneer" drug formula showed that their product, too, was then "generally recognized as safe" (Stepp, 1999) . This apparent void of FDA authority did not last long in keeping the FDA out of efficacy concerns, however. Instead of staying away from the issue, the "FDA took the position that the concept of drug safety can be viewed as a risk-benefit calculus, and, therefore, some consideration of efficacydthe benefit in the calculusdis inherent in the determination of safety" (Stepp, 1999) . This becomes the first of many examples where the FDA's administrative practices reflected its believed mission whether in the absence or presence of actual regulatory authority to act, and in such a manner, actually predicted its future legislative and regulatory state; a sort of "manifest destiny" of the FDA, if you will.
Despite the lack of actual authorities granted to monitor product efficacy, the FDA was running fairly smoothly with its creative definition strategy, coupled with a strategy to self-institute "a prescription-only drug system, …although it had no apparent statutory authority for such a system. [However,] … in 1951 Congress codified that system in the FDCA", showing further support for, and essentially the codification of, the FDA's mission to protect the public (Coleman, 2014) . These parallel strategies afforded the FDA an understood authority, if not a clearly defined one, to deter any release of products not specifically approved for specifically intended purposes. This situation would change in 1957 when the drug Thalidomide was widely prescribed to pregnant women across Europe as a sedative, resulting in an epidemic of birth defects known as "phocomelia" which often manifested as missing or malformed limbs in the surviving children. While it was never released in the U.S., the harmful effects were already known through a U.S. FDA trial. Without broader formal FDA authority, however, the product was released in Europe anyway (Stepp, 1999) . This event focused attention on the authority deficit and led directly, if not swiftly, to "the Drug Amendments of 1962" or Kefauver-Harris Amendments (Orlando, 1999) .
Commonly referred to as "The Amendments," this new set of rules expanded FDA authority via expanded scope of interstate commerce regulations, forbidding interstate commerce of any new drug that was not the subject of an NDA approved by and not merely in pursuit with FDA, or without the FDA's approval of the IND, not just IND filing, "thereby transforming the role of FDA from policeman to gatekeeper" by prohibiting the cross-stateline shipment of investigational drugs without the FDA's approval (Stepp, 1999) . These regulations also explicitly addressed expanded authority to review and approve efficacy merits on an indication-foruse basis, deciding that "each different therapeutic use of a product requires individual approval under the 1962 Amendments" thus creating a new "Supplemental NDA" for sponsors to apply for approval of new indications of already approved drugs, as well as newfound "control over the design and implementation of the clinical trial process" (Stepp, 1999) . Thus was born the modern clinical trial process which the FDA had been struggling to impose through its previous creative uses of definitions and scope creep.
This new authority was retroactively applied to pre-1962 drug approvals as well, a process in which drug sponsors would have the right to a hearing to defend their products against a ban. This created an obvious administrative burden the FDA would never be able to keep up with, so they again employed some creative definitions, this time for acceptable data collection and clinical trial design requirements. Essentially, the FDA required current-day, rigorous standards, which they had just created, be applied to any trials which produced submitted evidence of safety or efficacy. Thus any pre-1962 manufacturer would surely fail to live up to these standards and have no case for approval without starting from scratch to build sufficient clinical evidence of efficacy/safety data. The Supreme Court of the United States (SCOTUS) upheld this redefining tactic, demonstrating again a pivotal and supportive stance of the courts on behalf of the FDA (Stepp, 1999) . Coleman reflected that the "Supreme Court decisions that upheld FDA's position but, by using the abstract language loosely, permitted an interpretation that the decisions had gone far beyond what the FDA had argued, [so that t]welve years later, …FDA concluded that, although it had asked the Court for a little, it had been given a lot" (Coleman, 2014) .
Generics, too, were affected by these provisions, as their previous designation of "generally considered safe" clause was never approved or disapproved but instead now became dependent upon the pioneer NDA for approval, so that if a pre-1962 pioneer NDA became disapproved, so too did all dependent generic applications, which was again upheld by the SCOTUS, proving itself once again to be a pivotal actor in the successful authority expansion of the FDA and focusing of its mission of public health protection activities, as broadly defined as required (Stepp, 1999) .
Further regulations passed in the 1960's expanded the role of manufacturing oversight, leading to the current Good Manufacturing Practices (GMPs) in use today. These affect labeling, manufacturing plant standards, packaging and more, all required to have FDA approval and subject to inspection and seizure. All of these new regulations greatly reduced the speed at which a drug could secure an approval for release for public marketing. It wasn't until the 1980's when the delayed approval process had hit its peak of durations, coupled with other focusing events, that speed of approvals became a major political force which shifted the regulatory trend hitherto of increased scrutiny and expanded oversight, toward decreased approval times and streamlined regulatory processes. Manufacturers began to heavily pressure Congress to speed approval processes and President Ronald Reagan issued an executive order for "all Federal administrative agencies to assess their existing regulatory frameworks and to suggest potential reforms" which established the "Task Force" on Regulatory Relief, chaired by Vice President George H.W. Bush. Mr. Bush identified FDA approval processes among the top 20 reform-ready programs (Stepp, 1999) . Thus, DHHS pledged to reform both the FDA IND and NDA programs, and did so by 1982, again in 1987 and yet again in 1988 after V.P. Bush again led a task force to expedite treatment in lifethreatening circumstances (Stepp, 1999) .
The AIDS epidemic was a focusing event for many areas of Public Health and science in general during the 80's, but for the FDA, it was directly responsible for the creation of new expedited review and approval pathways, though resulting provisions were more broadly defined to include both life-threatening and severely-debilitating diseases such as "diseases or conditions that cause major irreversible morbidity (e.g., blindness or neurological degeneration)", "Expanded Availability", "Surrogate Endpoint" and "Parallel Track" investigations were all creatively drafted into new regulatory pathway options by 1992 to ensure greatest expediency and broadest access to experimental agents for terminal patients (Stepp, 1999) . These were all processes the FDA had administratively approved in the early days of the 80's AIDS epidemic despite lagging regulatory formalization well into the 90's (Stepp, 1999) . The FDA had not been waiting until formal authority or codified processes were passed to respond to the pressing political and public needs.
Another example of this propensity to act and then revise or update as needed is found in the device regulation side of FDA. The Medical Device Amendments (1976) to the 1938 Act were not written with allograft heart valve tissue in mind as that substance would not be invented for many years to come. However, the FDA had already "involved itself in the tissue banking community for many years … limited to … monitoring the activities of tissue banking, and engaging in dialogue with the tissue banking community. This passive role changed when the FDA's Center for Devices and Radiological Health (CDRH), announced a meeting to be held in June, 1990" wherein the FDA presented "requirements for the types of data to be submitted for premarket approval for mechanical or biological heart valves introduced into interstate commerce after the enactment of the 1976 Medical Device Amendments to the Food, Drug and Cosmetic Act," thereby creating the standard that henceforth, the FDA would be regulating heart valve allografts as Class III Devices, the most strictly regulated of the 3 classes of medical devices (Bottenfield and Deuel, 2005) . This prompted a consortium of industry representatives to file suit against the FDA, which again was dismissed by the FDA-friendly courts.
A few remaining evolutions of FDA approval regulations and processes warrant mention in this context; all are attempts to meet a need un-or underserved by existing FDA policies. The first is the emergence of Orphan Drug classifications. Two Acts in the early 80's created a frenzy of drug approvals. The first, known as the Bayh-Dole Act of 1980, "beloved by the biotechnology and investment communities" allowed scientists, universities, and small businesses to patent and profit from discoveries they made through federally funded research which they had not previously been able to do. This resulted in an increase in patents from 380 in 1980 to 3088 in 2009" (Markel, 2013) . In the second pivotal piece of patentrelated legislation, known as "The Drug Price Competition and Patent Restoration Act of 1984" or Hatch-Waxman Act, Congress created extensions to innovator drug patent terms and provided "provisions for the marketing of generic versions of patented drugs on the day after patent expiration" and "opportunities to challenge the validity of patents issued to innovator drug companies," thus creating a boon for generic development simply by clarifying the previously murky pathway (Melethil, 2005) . Fast forward to the new millennium, and the slowing pace of pharmaceutical innovation as evidence by lower rates of first-in-class and "blockbuster drug" approvals and growing patent expirations from those early filers in the 80's and 90's, and one can understand the need for the pharma industry to redesign itself away from blockbusters, toward "niche busters" also known as Orphan Drugs (Sharma et al., 2010) . The Orphan Drug Act of 1983 was intended to create incentive and pathways toward development of technologies to treat rare conditions as defined by low numbers of incident cases in the public. The Act has also been interpreted to cover "drugs that are not developed by the pharmaceutical industry for economic reasons but which respond to public health need" (Sharma et al., 2010) . The latter assignment of orphan status for economic reasons rather than quantitative rarity of condition to treat is a matter of public policy and politics and, as such, is highly subjective and rarely used.
Devised in the 90's, "Neglected Diseases" programs for tropical diseases typically impacted the impoverished nations south of the equator (Trouiller et al., 2002) , and "Accelerated Approval" programs for expedited approval pathways for terminal conditions, have all been developed in a similar fashion as Orphan Drug programs (Dagher et al., 2004; Orlando, 1999) . They have a targeted gap in broader FDA policy to fill, all with interdisciplinary collaborations with other Federal agencies (e.g., NIH and CDC most often), and with a mission to innovate safe and efficacious therapies to populations in need. Continuing this trend toward expedited fasttracks, 2013 saw the creation of a program for "Breakthrough Drugs" to spur continued focus on innovative new therapies in general, which has seen a robust response from industry with more than 200 requests for "breakthrough" designation to date (Wechsler, 2015) . How these programs will evolve and impact drug development remains to be seen, but the point has clearly been made that the FDA is willing to move beyond current policy confines in directions that "make sense" to meet new challenges as the evolving world of medicine and disease warrant.
How the Department of Defense (DOD) interacts with FDA
The DOD has always had to meet the unique medical needs of a battle-field-exposed service member population. Those requirements vary from extreme battlefield trauma, to occupational hazard exposures above and beyond limitations imposed on civilian workforces by Federal agencies (e.g., Occupational Safety and Health Administration, or "OSHA"), to chemical or biological warfare (CBW) exposures. The first and second of these have garnered much intramural as well as public-private partnership research focused on general improvements in emergency medical care or personal protective equipment (PPE) and generally follow traditional FDA pathways as they have evolved, to include "Emergency use" designations granted by the FDA for some exciting breakthroughs in areas like limb replacement and hemorrhage treatments. However, the CBW category has demanded new and innovative ways of working with the FDA to meet DOD requirements.
The DOD had $6.5 Billion in drug expenditures (a small fraction of all U.S. human-use drug sales) during the 2007 fiscal year, and provided care through its benefits program, TRICARE, to 9.2 Million active duty, retired military personnel and their dependents (Trice et al., 2009) . While the DOD is a purchaser of most DOD formulary drugs commercially, it can and does serve a role as developer of drugs and biologics (primarily vaccines) (Rettig et al., 2007) . Indeed, since 9e11 and resulting heightened war activities, the DOD has increasingly served as both the developer and sole purchaser (and thus sole market) of vaccines needed to thwart the likes of anthrax and other malicious CBW threats to national security. As the developer, the DOD is involved in the full spectrum of research activities and thus responsible to the FDA for all aspects of regulatory compliance, to include human clinical trials. However, it is obviously unethical to test known harmful agents on human populations, so the DOD worked closely with the FDA to create the 2002 "Two Animal Rule" whereby safety data in humans, combined with efficacy data in at least 2 animal models, could be submitted for market approval of a drug or biologic (Rettig et al., 2007; Martinez, 2007; Gronvall et al., 2007) .
However, outside of the CBW class, few drugs and biologics developed by the DOD ever "move beyond the IND stage, largely because few economic incentives exist for pharmaceutical firms to develop military useeonly products and because of the difficulty of generating data on efficacy" in an operational environment (Rettig et al., 2007) . Couple that with a well-documented understanding that the DOD is ill-equipped to handle drug development due to, among other cited reasons, a lack of centralized oversight, lack of mission focus or experience in clinical research, and, perhaps most detrimental, a "highly fragmented organizational structure" (Martinez, 2007) . This has led to chasms between developmental pathway stages, between basic science and product development, which leave technologies languishing in the "valley of death" of the advanced development/clinical trials stage (Martinez, 2007; Gottron, 2010) . To address that valley in CBW research, the then President of the United States, George W. Bush proposed project BioShield in 2003 and it was enacted in 2004 to ease the regulatory way for approval of successful treatments and prophylactic agents as well as create guaranteed government purchases in the billions of dollars (Gottron, 2010) . The market guarantee element was unprecedented in drug development, and drew sharp criticism for the potential wasted money, but it did successfully generate public and private research interest in an otherwise unattractive market. Nonetheless, Congressional scrutiny of BioShield, including its large leap from basic research to production (failing to address the need for mid-level/Advanced Development stages of research), and coupled with a Democratically controlled Congress pitted against a Republican President, led to creating the Biodefense Advanced Research and Development Authority (BARDA) in DHHS through the Pandemic and All-Hazards Preparedness Act (P.L. 109e417), as "a dedicated infrastructure to manage and fund advanced development and commercialization of CBRN countermeasures." While stopping short of canceling BioShield, Congress continued to fund BARDA through 20134 with sizable transfers from BioShield accounts (Gottron, 2010) . The intent of BARDA, like BioShield, was to take these specialty market requirements from IND to NDA successfully and timely. For lack of time here, I cannot go into the many reasons why these programs, perhaps not surprisingly, disappointed with meager product approvals to show for the billions invested in this partisan battle.
Hearing loss in the DOD population and FDA pipeline
Hearing loss affects millions of active duty service members and Veterans and is the most prevalent and expensive disability affecting Veterans as a direct result of service, according to every annual Veteran's Benefits Administration Annual Report for decades (VA, 2014) . Billions are spent annually in these disability costs alone, compounded by healthcare costs, quality of life degradation and any costs directly or indirectly assumed by the DOD. Yet there are very few clinical research studies completed to date examining safety or efficacy of a pharmaceutical intervention for the prevention or treatment of hearing loss. As the chair of a DOD working group on the subject, I can report that there are in fact less than half a dozen and none of them are close to applying for their NDA.
Pharmaceutical interventions for preventing or treating hearing loss have stalled for over 40 years since mechanisms of injury and proposed compounds were first identified to attack those mechanisms, even though there are now dozens of such compounds waiting on the doorstep of clinical trials. The problem can be boiled down to the same conundrum CBW trials faced e it is unethical to expose human beings to a harmful event in the name of research. Noise-induced hearing loss is largely preventable with proper PPE, so scientists cannot easily design an ethical clinical trial wherein subjects are not intentionally exposed to hazardous noise without proper protection. Military environments routinely expose service members to hazardous noise, but data limitations have prevented proper identification of ideal clinical trial subject pools to date. If the DOD were able to properly identify injured populations, it would have a moral imperative to immediately improve hearing conservation and prevention efforts to protect them, and the scientist would go back to the drawing board.
Conclusions
A precedent exists, set recently and much more dramatically seen in the CBW vaccine developments, of creative and collaborative work between the FDA and the DOD to achieve necessary requirements together. Further, there is precedent in the FDA for maintaining a high level of flexibility and dedication to filling under-served populations. As exemplified in the recent convergence and policy action points of 1) political (Congressional and Presidential engagement), 2) policy (of the FDA and similar international regulatory bodies) and 3) problem (under-served poverty markets, niche/orphan populations or emergent threat response requirements) streams, opportunities to create specialized categorical development pathways can be created and seized (Kingdon, 2011) . The currently stymied field of hearing loss pharmaceuticals could follow suit by creating its own metaphorical "wave of opportunity" in which to push forward (Kingdon, 2004) .
Primary actors in FDA policy process include other Federal agencies like the DOD and the Congressional and Presidential actors who are generally very supportive of DOD troop health issues. The courts have been historically friendly toward FDA prudence of regulatory authority and interpretative policies when public welfare is at the heart of the matter, and industry would benefit from development in this area with potentially one of the largest markets in pharmaceutical history laying in the balance (Coleman, 2014) .
The fact remains that the FDA has demonstrated itself to be highly influenced by its stakeholders e from patient advocacy groups, the medical community, other Federal agencies, U.S. leadership, and industry e and all of these groups have a converging interest in preventing or curing hearing loss. There has to be a policy entrepreneur to bring these positions together; a "mobilization of drug-specific lobbiesdthe firms and the patients" (Carpenter, 2004) . I posit that none could be more appropriate or better poised to serve that function than the DOD itself with an economic interest, moral imperative to its troops, history of regulatory creativity and collaboration with the FDA, mandate to serve as both producer and purchaser if need be, and the political clout to force the conversation. "FDA drug review is an exercise in learning shaped by organized interests" and the FDA remains highly responsive to "opinion leaders" (Carpenter, 2004) . Further, the FDA "has been punctuated by periods of growth and retrenchment as the political climate for regulation has responded to events, interest groups, and ideology" (Eisenberg, 2007) . The hearing loss research interest groups stand at a pivotal juncture where the possibility of a successful development pathway is only an organized response to the FDA away.
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